New quality standards for MDMA and psilocybinez
28 Aug 2024
Two new quality standards, one for MDMA and another for psilocybine, have been published. These standards each specify the minimum quality requirements for both the active pharmaceutical ingredient (API) and finished product.
Commencement
The quality standards have been registered as Therapeutic Goods Orders (TGOs) on the Federal Register of Legislation:
- Therapeutic Goods (Standard for MDMA) Order 2024 (TGO 112)- external site
- Therapeutic Goods (Standard for psilocybine) Order 2024 (TGO 113).- external site
From 6 January 2025, all MDMA and psilocybine API and finished products supplied or manufactured in Australia must comply with the relevant TGO.
Guidance material
We will publish guidance material to help manufacturers and sponsors understand how these TGOs set the minimum quality requirements that must be met for these medicines.
Categories
- MBS
- PBS
- The Department Of Health And Aged Care
- RACGP
- NIP
- AHPRA
- NSW Health
- Queensland Health
- Victoria Health
- Tasmania News
- Western Australia
- SA Health
- NT HEALTH
- Pharmacy Board Of Ahpra
- National Asthma Council
- NT
- AMA
- NACCHO
- BCNA
- Australian College Of Nurse Practitioners
- Asthma Australia
- LFA
- Palliative Care
- Primary Health Network
- AIHW
- Children's Health Queenland
- Kidney Health
- CHF
- MHC
- Gold Coast
- Tsa
- TGA
Popular Posts
Tags
- Environmental health National Health and Climate Strategy environmental-health-national-health-and-climate-strategy